Thread by @JennyCarlisleMD

@TumorBoardTues @LealTiciana 1/21 #TumorBoardTuesday #LungCancer #OncTwitter

47yo 👨🏽‍💼🚭
No significant PMHx
Incidental 📏 2.8cm cavitary RLL nodule on coronary calcium scan in 2020
FDG 💥on PET with hilar LN 💥
🫁🎥 Mediastinoscopy shows adenocarcinoma, + subcarinal LN (stage IIIA)

🤨 How would you treat?

@TumorBoardTues @LealTiciana 2/21 #TumorBoardTuesday
Due to findings👆🏽
👨🏽‍💼Began Neoadjuvant cisplatin/pemetrexed x 4
✂️lobectomy in 2020

ChemoIO was not SOC in 2020.
✨Checkmate 816
📍patients excluded if they had EGFR and ALK alterations:
📚@FordePatrick @DrMarkAwad @JulieBrahmer nejm.org/doi/full/10.10…

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @FordePatrick @RamalingamMD @RachelSanbornMD @KarenReckampMD @DrMarkAwad @JulieBrahmer @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD 3/21 #TumorBoardTuesday @LealTiciana
👨🏽‍💼Began @NCCN surveillance nccn.org/professionals/…
🗓️H&P + chest CT ± contrast q 6mo for 2–3y
🗓️then H&P + low-dose non– contrast-enhanced chest CT yearly
📅2021 (≈5 mo later): scans ➡️ multi 🦴mets

🤔What’s your method of molecular testing?

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN 5/21 #TumorBoardTuesday @JohnEbbenMDPhD
👩🏻‍🏫Mini tweetorial 2👩🏼‍🏫
📌Tumor NGS

💥Hot spot testing & PCR can miss ex 20 insertions💥

PCR tests would have missed 40% of pts with NSCLC with EGFR ex20ins mutations‼️
🥇NGS-based testing preferred
📚@oncoOuLungCA jto.org/article/S1556-…

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @LeXiuning @BrendonStilesMD @LaurenByersMD @rohit_thum @drgandara @DrJNaidoo @aakonc @Polarbear900R @SamuelKareffMD

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @LeXiuning @BrendonStilesMD @LaurenByersMD @rohit_thum @drgandara @DrJNaidoo @aakonc @Polarbear900R @SamuelKareffMD 6/21 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 3 👩🏼‍🏫
📌EGFR exon 20 mutations
🔸4-10% of EGFR mutations in #NSCLC

🔸generally associated with lack of response to 1st, 2nd, & 3rd-gen EGFR TKI
📚Vyse & Huang, @Nature 2019 nature.com/articles/s4139…

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @LeXiuning @BrendonStilesMD @LaurenByersMD @rohit_thum @drgandara @DrJNaidoo @aakonc @Polarbear900R @SamuelKareffMD @Nature 7/21 #TumorBoardTuesday #LungCancer #LCSM
👩🏻‍🏫Mini tweetorial 4 👩🏼‍🏫

📌EGFR exon 20 insertions/mutations

📍Most are diverse group of in-frame duplication or insertion muts
📍Associated with response to specific 🎯 subsequent therapy

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @LeXiuning @BrendonStilesMD @LaurenByersMD @rohit_thum @drgandara @DrJNaidoo @aakonc @Polarbear900R @SamuelKareffMD @Nature 8/21 #TumorBoardTuesday #LCSM
👩🏻‍🏫Mini tweetorial 5 👩🏼‍🏫

✨Chrysalis trial ✨

📍First-in-human
📍phase I dose-escalation, & dose-expansion (NCT02609776)
📍evaluated efficacy, safety, & pharmacokinetics of amivantamab in pts with adv #NSCLC

📚Park K @JSabari pubmed.ncbi.nlm.nih.gov/34339292/

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @LeXiuning @BrendonStilesMD @LaurenByersMD @rohit_thum @drgandara @DrJNaidoo @aakonc @Polarbear900R @SamuelKareffMD @Nature 9/21 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 6 👩🏼‍🏫

✨Chrysalis✨

📌Amivantamab-vmjw: EGFR-MET bispecific antibody
📚doi.org/10.1158/2159-8…

📌Response to amivantamab after plat-based chemo in pts with EGFR Exon20ins muts
✅ORR: 40%
✅median DOR: 11.1 mon
✅median PFS: 8.3 mon

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 10/21 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 7 👩🏼‍🏫

✨Chrysalis✨

👍🏽results led to accelerated @US_FDA approval May 2021
📚@JSabari @RachelSanbornMD @KarenReckampMD fda.gov/drugs/resource…

@Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 11/21 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 8👩🏼‍🏫

✨PPP cohort/EXCLAIM trial✨

Phase 1/2
nonrandomized
dose-escalation/dose-expansion cohorts
single-arm extension cohort (EXCLAIM)

1° analysis: plat-pretreated pts (PPP) cohort & EXCLAIM cohort

📌Mobocertinib: EGFR Exon 20 TKI

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 12/21 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 9
✨PPP/EXCLAIM
👍🏽results led to accelerated @US_FDA approval in 2021
📚@RamalingamMD ncbi.nlm.nih.gov/pmc/articles/P…

📌Response to mobocertinib in EGFR ex20 post plat doublet (PPP cohort)
✅ORR: 28%
✅median DOR: 17.5 mon
✅median PFS: 7.3 mon

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 13/21 #TumorBoardTuesday
Back to our case 🔎

nccn.org/professionals/…

🤔 Which EGFR exon 20 therapy PPP should we choose first?

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 14/21 #TumorBoardTuesday
Back to case🔎
47yo👨🏽‍💼
EGFR ex20
s/p neoadju Cis/alimta
widespread🦴mets
👉🏽amivantamab IV
👉🏽Infusion related reaction (IRR) on C1D1
🤔When to switch or rechallenge?

Developed g2 IRR with HTN
➡️ responded to IV fluids + methylpred & diphenhydramine
Next?

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 15/21 #TumorBoardTuesday
✨Chrysalis

IRRs were common:
66% occurred on cycle 1, day 1 (93%) or day 2 (4%; first dose is split over 2 days)
Rarely recurred with subsequent dosing
Majority of IRRs grade 1-2
Predisposing factors not identified

See images of Adverse Events (AEs)

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 16/21 #TumorBoardTuesday #NSCLC #LungCancer

✨Chrysalis

📌 IRR Mitigation Strategies:

📆 Splitting the first dose over 2 days
💊 Administration of prophylactic premedication
🧑‍🏫 Education of infusion clinic staff and patients

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 17/21 #TumorBoardTuesday #NSCLC #LungCancer

✨PPP/EXCLAIM

📌Common Adverse Events (AEs)

Diarrhea
Rash
Paronychia
Decreased appetite
Nausea
Dry skin
Vomiting
Creatinine increase
Stomatitis

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily 18/21 #TumorBoardTuesday #LCSM
📌Amivantamab vs Mobocertinib
🕵🏻Cross trial comparison, done with stats!
⚓️unanchored matching-adjusted indirect comparison (MAIC)
Efficacy outcomes: compared between weighted amivan vs mobocert patients
📚@oncoOuLungCA @ASCO ascopubs.org/doi/abs/10.120…

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO 19/21 #TumorBoardTuesday #LungCancer
📌Amivantamab vs Mobocertinib

⚓️ unanchored matching-adjusted indirect comparison (MAIC) method showed similar efficacy

🤞🏽Having 2 options with differing MOA may be an advantage
🤔 Limitations? What about side effects?

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO 20/21 #TumorBoardTuesday

🤔Emerging strategies in EGFR exon 20?

Ongoing phase 3 studies investigating 1L role
✨PAPILLON
🔗clinicaltrials.gov/ct2/show/NCT04…
✨EXCLAIM-2
🔗clinicaltrials.gov/ct2/show/NCT04…

@ZPiotrowskaMD gave an excellent overview at #TTLC23 on EGFR Exon 20 Targeting Drugs

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO @ZPiotrowskaMD 21/21 #TumorBoardTuesday
Back to our case 🔎

👨🏽‍💼Patient was rechallenged with implementation of IRR mitigation strategies.
🙏🏼 He did well and remains on amivantamab.

Thanks for joining! 🙏🏽

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval23
👉🏽ALL CME🔗 integrityce.com/TBT2023

🤔@LealTiciana @JennyCarlisleMD taught us EGFR ex20ins #NSCLC, test your🧠

47yo👨🏼‍🦱
Multi 🦴mets post neoadju chemo
✂️loboectomy
+EGFRex20ins
🧐Which therapy would you pick

@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20Group @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2023

47yo 👨🏼‍🦱 elected to receive amivantamab
Developed grade 2 infusion-related HTN that responded to IV fluids, methylprednisolone, and diphenhydramine.

🧐 What is your next step?